GlaxoSmithKline to buy cancer-focused Tesaro for $5.1 billion
In buying the US-based company for a 110 percent premium over its average 30-day share price, GSK hopes to beef up its oncology pipeline.
Zejula
In buying the US-based company for a 110 percent premium over its average 30-day share price, GSK hopes to beef up its oncology pipeline.